J
Joel Veiga
Researcher at University of Paris
Publications - 2
Citations - 262
Joel Veiga is an academic researcher from University of Paris. The author has contributed to research in topics: Ineffective erythropoiesis & Autocrine signalling. The author has an hindex of 1, co-authored 2 publications receiving 234 citations.
Papers
More filters
Journal ArticleDOI
An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia
Michael Dussiot,Thiago Trovati Maciel,Aurélie Fricot,Céline Chartier,Olivier Negre,Joel Veiga,Damien Grapton,Etienne Paubelle,Emmanuel Payen,Yves Beuzard,Philippe Leboulch,Jean-Antoine Ribeil,Jean-Benoît Arlet,Francine Côté,Geneviève Courtois,Yelena Ginzburg,Thomas O. Daniel,Rajesh Chopra,Victoria Sung,Olivier Hermine,Ivan C. Moura +20 more
TL;DR: Observations suggest that ActRIIA ligand traps may have therapeutic relevance in β-thalassemia by suppressing the deleterious effects of GDF11, a cytokine which blocks terminal erythroid maturation through an autocrine amplification loop involving oxidative stress and α-globin precipitation.
Journal ArticleDOI
Modulation of Activin Signaling by RAP-011 (ActRIIA-IgG1) Improve Anemia, Increases Hemoglobin Levels and Corrects Ineffective Erythropoiesis in β-Thalassemia
Michael Dussiot,Thiago Trovati Maciel,Aurélie Fricot,Joel Veiga,Etienne Paubelle,Emmanuel Payen,Yves Beuzard,Jean-Antoine Ribeil,Jean-Benoît Arlet,Geneviève Courtois,Thomas O. Daniel,Rajesh Chopra,Victoria Sung,Olivier Hermine,Ivan C. Moura +14 more
TL;DR: Sotatercept (a humanized version of RAP-011) is currently in phase II clinical trials for treatment of anemia in patients with Myeloma Bone Disease and End Stage Renal Disease and data from the non-clinical findings support a newly initiated β-thalassemia clinical trial.